Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

Autor: Michiel Rienstra, Debra Marshall, William T. Abraham, Michel White, Ian A. Carroll, Sophia P. Huebler, Ryan Aleong, Dirk J. van Veldhuisen, Stephen B. Wilton, William H. Sauer, Stuart J. Connolly, Jonathan P. Piccini, Inder S. Anand, Christopher M. O'Connor, Jeff S. Healey, Christopher Dufton, Michael R. Bristow

Publikováno v: Heart rhythm O2, 3(1), 40-49

Background: Heart failure (HF) patients with atrial fibrillation (AF) often have conduction system disorders, which may be worsened by β-blocker therapy.Objective: In a post hoc analysis we examined the prevalence of bradycardia and its association

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66c86dcdd227d41b4d3c403bd96061ea
https://doi.org/10.1016/j.hroo.2021.11.005

Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype

Autor: Jonathan P. Piccini, Christopher Dufton, Ian A. Carroll, Jeff S. Healey, William T. Abraham, Yaariv Khaykin, Ryan Aleong, Steven K. Krueger, William H. Sauer, Stephen B. Wilton, Michiel Rienstra, Dirk J. van Veldhuisen, Inder S. Anand, Michel White, A. John Camm, Paul D. Ziegler, Debra Marshall, Michael R. Bristow, Stuart J. Connolly, F Ayala-Paredes, A Bakbak, ML Bernier, DH Birnie, B Coutu, E Crystal, MW Deyell, KM Dyrda, MC Hartleib, ZW Laksman, P Leong-Sit, CA Morillo, AS Pandey, F Philippon, S Vizel, P Andréka, Z Csanadi, GZ Duray, T Forster, G Kerkovits, B Merkely, AC Nagy, T Simor, D Czarnecka, JD Kasprzak, WJ Musial, G Raczak, J Szachniewicz, JK Wranicz, S Apostolović, S Hinić, V Miloradović, D Simić, GJ Milhous, A Oomen, TJ Romer, LM van Vijk, PB Adamson, JD Allred, N Amjadi, MM Bahu, AJ Bank, AE Berman, MA Bernabei, RS Bhagwat, L Borgatta, AJ Buda, RT Cole, JL Collier, SJ Compton, O Costantini, MR Costanzo, IM Dauber, MP Donahue, I Dor, GF Egnacyzk, EJ Eichhorn, CC Eiswirth, S Emani, GA Ewald, RC Forde-McLean, MD Gelernt, DE Haines, CA Henrikson, JM Herre, B Herweg, L Ilkhanoff, LR Jackson, A Lala, R Lo, B London, BD Lowes, JA Mackall, V Malhotra, FA McGrew, S Murali, A Natale, KR Nilsson, J Okolo, MV Perez, RS Phang, R Ranjan, MY Rashtian, MJ Ross, SM Samii, T Shinn, MB Shoemaker, SA Strickberger, VN Tholakanahalli, A Tzur, PJ Wang, LT Younis

Publikováno v: Circulation. Arrhythmia and Electrophysiology, 14(8):009591. LIPPINCOTT WILLIAMS & WILKINS

Background: Bucindolol is a genetically targeted β-blocker/mild vasodilator with the unique pharmacological properties of sympatholysis and ADRB1 Arg389 receptor inverse agonism. In the GENETIC-AF trial (Genotype-Directed Comparative Effectiveness T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b3b46d4e71ba0e2188b0ff7e480073
https://research.rug.nl/en/publications/e4da658b-c78f-4c9f-a6ea-3c34cd1b9426

Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial

Autor: Jonathan P, Piccini, William T, Abraham, Christopher, Dufton, Ian A, Carroll, Jeff S, Healey, Dirk J, van Veldhuisen, William H, Sauer, Inder S, Anand, Michel, White, Stephen B, Wilton, Ryan, Aleong, Michiel, Rienstra, Steven K, Krueger, Felix, Ayala-Paredes, Yaariv, Khaykin, Bela, Merkely, Vladimir, Miloradović, Jerzy K, Wranicz, Leonard, Ilkhanoff, Paul D, Ziegler, Gordon, Davis, Laura L, Emery, Debra, Marshall, David P, Kao, Michael R, Bristow, Stuart J, Connolly

Publikováno v: JACC. Heart failure. 7(7)

The purpose of this study was to compare the effectiveness of bucindolol with that of metoprolol succinate for the maintenance of sinus rhythm in a genetically defined heart failure (HF) population with atrial fibrillation (AF).Bucindolol is a beta-b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::03256c8937c19dd9699a45605f428e34
https://pubmed.ncbi.nlm.nih.gov/31248570

Clinical Pharmacokinetics and Drug-Drug Interactions of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

Autor: Christopher Dufton, Jürgen Venitz, Hunter Gillies, Martine Allard, Jean Regnault, Julia Zack

Publikováno v: The Journal of Clinical Pharmacology. 52:1784-1805

The authors review the basic pharmacology and potential for adverse drug-drug interactions (DDIs) of bosentan and ambrisentan, the 2 endothelin receptor antagonists currently approved for pulmonary arterial hypertension (PAH) treatment. Bosentan, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a93ec109f050f8d010ee29ccc4a9f3d
https://doi.org/10.1177/0091270011423662

Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?

Autor: Christopher Dufton, Mardi Gomberg-Maitland, Raymond L. Benza, Ronald J. Oudiz

Publikováno v: Journal of the American College of Cardiology. 57:1053-1061

Pulmonary arterial hypertension (PAH) is a rare and progressive disease of the pulmonary arterial circulation that is characterized by a progressive rise in pulmonary vascular resistance, eventually leading to right-heart failure and death. There are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::998b7ee0d153209deb659433e9d7a7d4
https://doi.org/10.1016/j.jacc.2010.11.020